Direct effect of GLP-1 infusion on endogenous glucose production in humans

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Diabetologia

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00125-012-2738-3PMID 23064290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

  2012cited by this paper
• Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients.

  2011cited by this paper
• Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis

  2011cited by this paper
• GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes.

  2011cited by this paper
• Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

  2010cited by this paper
• The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action.

  2009cited by this paper
• Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.

  2008cited by this paper
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.

  2007cited by this paper
• Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.

  2007cited by this paper
• GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting

  2007cited by this paper
• Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects.

  2006cited by this paper
• Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

  2005cited by this paper
• Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.

  2003influential reference
• Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.

  2002cited by this paper
• Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes.

  2001cited by this paper
• Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.

  2001cited by this paper
• Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo.

  2001cited by this paper
• Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

  2000cited by this paper
• Assessment of methods for improving tracer estimation of non-steady-state rate of appearance.

  1999cited by this paper
• Effects of Glucagon-Like Peptide 1 (7–36 Amide) on Glucose Kinetics during Somatostatin-Induced Suppression of Insulin Secretion in Healthy Men

  1998cited by this paper
• Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.

  1997cited by this paper
• Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions.

  1997cited by this paper
• Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.

  1996cited by this paper
• The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

  1996cited by this paper
• Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.

  1994cited by this paper
• Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

  1993cited by this paper
• The theoretical bases of indirect calorimetry: a review.

  1988cited by this paper
• Measurement of size and turnover rate of body glucose pool by the isotope dilution method.

  1956cited by this paper

• Metformin-mechanisms of its glycemia-reducing effect.

  2025cites this paper
• Effects of probiotics and synbiotics supplementation on cardiovascular risk factors in adults with prediabetes: a GRADE-assessed systematic review and meta-analysis of RCTs

  2025cites this paper
• Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)

  2024cites this paper
• GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

  2024cites this paper
• Hepatic function of glucagon-like peptide-1 and its based diabetes drugs

  2024cites this paper
• GLP-1 receptor agonist treatment improved fasting and postprandial lipidomic profile independently of diabetes and weight loss.

  2024cites this paper
• GLP‐1 enhances β‐cell response to protein ingestion and bariatric surgery amplifies it

  2024cites this paper
• Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases

  2024cites this paper
• A Comprehensive Review on GLP-1 Signaling Pathways in the Management of Diabetes Mellitus - Focus on the Potential Role of GLP-1 Receptors Agonists and Selenium Among Various Organ Systems.

  2024cites this paper
• Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism

  2024cites this paper
• Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery

  2024cites this paper
• Hepatic glucose metabolism in the steatotic liver

  2024cites this paper
• The Role of Probiotics in Managing Glucose Homeostasis in Adults with Prediabetes: A Systematic Review and Meta-Analysis

  2024cites this paper
• Tirzepatide a novel anti diabetic molecule unfold dual action

  2024cites this paper
• GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease

  2023cites this paper
• Glycemia and Gluconeogenesis with Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.

  2023cites this paper
• Contribution of endogenous glucagon-like peptide 1 to prandial counterregulatory responses to hypoglycemia after bariatric surgery

  2023cites this paper
• The intestine as an endocrine organ and the role of gut hormones in metabolic regulation

  2023cites this paper
• Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets

  2023cites this paper
• An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease.

  2023cites this paper
• Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy.

  2022cites this paper
• Prediabetes blunts DPP4 genetic control of postprandial glycaemia and insulin secretion

  2022cites this paper
• Evaluation of renal glucose uptake with [18F]FDG-PET: Methodological advancements and metabolic outcomes.

  2022cites this paper
• Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease.

  2022influential citation
• SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease.

  2022cites this paper
• Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists

  2022cites this paper
• Momordica charantia nanoparticles potentiate insulin release and modulate antioxidant gene expression in pancreas of diabetic rats

  2022cites this paper
• The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity.

  2021cites this paper
• Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge

  2021cites this paper
• Exogenous GLP-1 Stimulates TCA Cycle and Suppresses Gluconeogenesis and Ketogenesis in Late-fasted Northern Elephant Seals Pups.

  2021cites this paper
• Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach

  2021cites this paper
• Hypoglycemic Effects of Rosa damascena Mill. Ethanolic Extract on Blood Glucose Levels and Diameter of Langerhans Pancreatic Islets

  2021cites this paper
• Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice.

  2021cites this paper
• The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror

  2021cites this paper
• Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease

  2021cites this paper
• Prediabetes Blunts CD26/DPP4 Genetic Control of Postprandial Glycemia and Insulin Secretion

  2021cites this paper
• The pathophysiology of gut–liver connection

  2021cites this paper
• The Postprandial Glycaemic and Hormonal Responses Following the Ingestion of a Novel, Ready-to-Drink Shot Containing a Low Dose of Whey Protein in Centrally Obese and Lean Adult Males: A Randomised Controlled Trial

  2021cites this paper
• Liver-targeting drugs and their effect on blood glucose and hepatic lipids

  2021influential citation
• Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation

  2020cites this paper
• Incretins in obesity and diabetes

  2020cites this paper
• The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes.

  2020cites this paper
• Role of intestinal glucose absorption in glucose tolerance.

  2020cites this paper
• NAFLD and Insulin Resistance: A Multisystemic Disease

  2020cites this paper
• The Clinical Application of Mealtime Whey Protein for the Treatment of Postprandial Hyperglycaemia for People With Type 2 Diabetes: A Long Whey to Go

  2020cites this paper
• Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH

  2020cites this paper
• Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein

  2020cites this paper
• Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial

  2020cites this paper
• Thymoquinone activates imidazoline receptor to enhance glucagon-like peptide-1 secretion in diabetic rats

  2019cites this paper
• Perioperative infusion of glucagon like peptide-1 prevents insulin resistance after surgical trauma in female pigs.

  2019cites this paper
• GLP‐1 induces alpha cell proliferation and overrides leptin suppression induced by negative energy balance in vagotomized rats

  2019cites this paper
• Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.

  2019cites this paper
• GLP‑1 improves palmitate‑induced insulin resistance in human skeletal muscle via SIRT1 activity.

  2019cites this paper
• Mechanism of glucose‐lowering by metformin in type 2 diabetes: Role of bile acids

  2019influential citation
• Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications.

  2019cites this paper
• From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

  2019cites this paper
• Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues

  2019cites this paper
• Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance

  2018cites this paper
• Lipotoxicity and the gut-liver axis in NASH pathogenesis.

  2018cites this paper
• DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes.

  2018cites this paper
• Incretin hormones: Their role in health and disease

  2018cites this paper
• The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus

  2018cites this paper
• Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans

  2018cites this paper
• Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment

  2018cites this paper
• Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review

  2018cites this paper
• Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

  2018cites this paper
• Overview of Glucose Homeostasis

  2018cites this paper
• Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.

  2018cites this paper
• Insulin and Glucagon: Partners for Life

  2017cites this paper
• Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1

  2017cites this paper
• Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

  2017cites this paper
• Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß‐cell function in non‐diabetic, morbidly obese patients

  2017cites this paper
• GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products

  2017cites this paper
• Glucagon‐like peptide‐1 and glucose‐dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice

  2017cites this paper
• Fenugreek Compound (N55) Lowers Plasma Glucose through the Enhancement of Response of Physiological Glucagon-like peptide-1

  2017cites this paper
• Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats

  2017cites this paper
• Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

  2017cites this paper
• The Dietary Furocoumarin Imperatorin Increases Plasma GLP-1 Levels in Type 1-Like Diabetic Rats

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance

  2017cites this paper
• Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.

  2017cites this paper
• Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats.

  2017cites this paper
• GLP-1 based therapies: clinical implications for gastroenterologists

  2016cites this paper
• Kohlenhydratstoffwechsel der Leber

  2016cites this paper
• A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes

  2016cites this paper
• Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

  2016cites this paper
• Incretins.

  2016cites this paper
• Glucagon-like peptide-1 loaded phospholipid micelles for the treatment of type 2 diabetes: improved pharmacokinetic behaviours and prolonged glucose-lowering effects

  2016cites this paper
• Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

  2016cites this paper
• Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?

  2016cites this paper
• Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion.

  2016cites this paper
• Gastrointestinal mediation of glucose homeostasis and postprandial cardiovascular risk

  2016cites this paper
• Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action

  2016cites this paper
• Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.

  2016influential citation
• Glucagon-Like Peptide 1 Decreases Lipotoxicity in Non-Alcoholic Steatophepatitis

  2016cites this paper
• Sicurezza ed efficacia della liraglutide in pazienti con steatoepatite non alcolica (LEAN): uno studio di fase 2, multicentrico, doppio cieco, randomizzato, con controllo placebo

  2016cites this paper
• Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

  2016cites this paper
• Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes

  2016cites this paper
• Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.

  2016cites this paper
• Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives.

  2016influential citation